# A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

> **NCT01853306** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 71 (actual)

## Conditions studied

- Oncology
- BRCA Mutated
- High Grade Serous Ovarian Cancer
- BRCA Mutated Breast Cancer

## Interventions

- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01853306
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-18
- **Primary completion:** 2017-05-03
- **Final completion:** 2017-06-29
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01853306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01853306, "A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01853306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*